 Genfit SA NASDAQ: GNFT shares are trading higher after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. David Loew, Chief Executive Officer, Ipsen, said, Todays announcement marks an exciting new stage in Ipsens ambitions to expand our portfolio to support more people living with rare diseases around the world. 